Drug Approval | April 29, 2026
AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata
After Phase 3 results show major hair regrowth gains
After Phase 3 results show major hair regrowth gains
The submission is backed by positive results from the Phase 3 AFFIRM study
Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing
Highlights Mirvetuximab-based regimen promise
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
This study evaluated a difficult-to-treat Crohn's disease patient population
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Improvements were also seen in complete response rates, duration of response, and time to next treatment
Subscribe To Our Newsletter & Stay Updated
